Weight Loss Jabs Scarce on NHS in Scotland Amidst Private Demand

Fewer than 800 individuals in Scotland have received weight loss injections through the National Health Service (NHS), according to a BBC News investigation. This comes despite the medications, such as Wegovy and Mounjaro, being approved for weight loss use up to three years ago. The limited availability on the NHS contrasts sharply with a surge in private prescriptions for these drugs.

Currently, only five of Scotland's 14 health boards offer these treatments specifically for weight loss, and even then, only as part of small pilot programs. Doctors are calling the situation "discriminatory," arguing that the lack of widespread NHS access exacerbates existing health inequalities. A significant portion of the Scottish population, approximately one-third, is classified as obese, a condition linked to serious health issues including cardiovascular disease, cancer, and diabetes.

Mounjaro received approval for NHS weight loss use in Scotland in 2023, followed by Wegovy in 2024. However, freedom of information requests revealed that only a handful of health boards, including NHS Forth Valley, NHS Borders, NHS Lothian, NHS Lanarkshire, NHS Western Isles, and the NHS State Hospital, are prescribing these drugs for weight loss as part of pilot schemes. By September 2026, a total of 705 patients had received these injections through these limited programs. In contrast, an estimated 300,000 people are believed to be accessing the drugs privately.

The Scottish government stated that these medications are part of a broader range of obesity treatments and that decisions on their availability rest with individual health boards. These boards are guided by a National Consensus Statement, which recommends a phased introduction of obesity medicines based on a patient's body mass index and any related health conditions.

Kathleen McLaughlin, a 54-year-old from Laurieston, is one of the patients benefiting from the NHS Forth Valley pilot. Referred due to her weight hindering necessary surgery, she had previously struggled with weight loss and now faces arthritis and mobility issues. "It stops your life progressing. You're just vegetating your life away," she stated. McLaughlin expressed gratitude for the opportunity to receive the injections under medical supervision, rather than pursuing private options without support. Since April, she has lost four stone, improving both her physical and mental health.

The Forth Valley pilot program, based at Falkirk Community Hospital, has strict criteria for patient selection, requiring a BMI of 40 or above and at least four serious medical conditions, or the need for life-altering surgery. The pilot currently includes 48 patients, with an additional 18 receiving the drugs via GP practices. However, the service is not accepting new referrals during the pilot phase.

Dr. Mark Strachan, a diabetes specialist and president of the Royal College of Physicians, described the limited progress as "unacceptable." He highlighted the substantial costs incurred by the NHS in treating obesity complications and argued that investing in interventions for the underlying condition would be more effective. While acknowledging that widespread NHS provision could be financially challenging, Dr. Strachan advocated for a targeted rollout to high-risk individuals, emphasizing the drugs' safety and potential cost-effectiveness.

Doctors have also raised concerns about the high volume of private prescriptions, suggesting it deviates from established safe prescribing practices within the NHS. With obesity disproportionately affecting lower-income populations, the disparity in access is seen as widening health inequalities.

Dr. Jane Sehgal, a GP and health coach, noted the complexity of managing weight loss, which is influenced by various lifestyle factors such as sleep, stress, and relationships. She stressed the importance of addressing behavioral and lifestyle aspects alongside medical interventions. Sabriena Clayton, 48, who began private treatment after her BMI indicated eligibility for NHS use, reported losing three stone and experiencing improved well-being.

Despite these concerns and patient testimonials, the Scottish government maintains that health boards are responsible for medication availability decisions, supported by national guidelines that advocate for a measured approach to introducing obesity medicines.